Related coverage linked through entity extraction aliases.
Mar 30, 2026
Roche Holding AG shares show potential undervaluation despite strong returns, with DCF models suggesting 59% upside. The pharmaceutical giant trades at P/E ratios below fair value estimates while maintaining solid financial performance and dividend growth. Recent pipeline developments and product innovations support long-term growth prospects.
Mar 29, 2026
The phase 3 ENVISION trial shows 80% complete response rate for novel bladder cancer chemoablative therapy. AI integration accelerates precision oncology through biomarker identification and targeted treatments. OncoPRO real-time symptom monitoring system enhances patient safety and clinical trial data capture.
Mar 29, 2026
InSilico Medicine and Eli Lilly have entered a major AI drug discovery collaboration potentially worth $2.75 billion, with Lilly gaining exclusive rights to develop preclinical oral therapies. InSilico will receive $115 million upfront plus milestone payments and royalties. The deal reflects increasing pharmaceutical industry adoption of AI platforms to accelerate drug development.
Mar 28, 2026
Moderna shares declined nearly 6% amid extreme options market volatility and a new patent infringement lawsuit from BioNTech. The company faces significant financial challenges with negative earnings and declining revenue growth, while valuation metrics suggest potential overvaluation. Technical indicators point to bearish short-term momentum as the stock approaches key support levels.
Mar 24, 2026
The FDA has eased biosimilar approval procedures as these therapies have generated $56 billion in savings since 2015. New guidance eliminates comparative efficacy studies, potentially saving manufacturers $100 million per product and cutting development time by 50%. Despite growth to 23% of the biologics market, a "biosimilar void" threatens $232 billion in missed savings over the next decade.
Mar 24, 2026
The AI-driven precision medicine market is projected to grow from $0.7 billion in 2025 to $9.7 billion by 2035 at a 26.8% CAGR. North America dominates with 62-67% market share, while machine learning accounts for 39% of the market. The market is moderately consolidated with the top five players controlling over 64% share.
Mar 24, 2026
Dana-Farber Cancer Institute will host the Fifth Transatlantic Exchange in Oncology on March 27, 2026, featuring discussions on epigenetic therapies, microbiome-driven immunity, and cellular pathway reprogramming. The event continues collaboration between Dana-Farber and France's Gustave Roussy cancer center with support from L'Institut Servier and Medscape Medical Affairs.
Mar 23, 2026
Monash University and Ono Pharmaceutical have signed two licence agreements for the development of anti-GPCR antibodies targeting autoimmune and inflammatory diseases. The agreements result from Ono exercising options on research collaborations announced in 2023. The partnership combines Monash's research excellence with Ono's drug development capabilities to address unmet medical needs.
Mar 23, 2026
The global generic drugs market reached $389 billion in 2024 and is projected to grow to $675 billion by 2033. In the U.S., generics account for 91% of prescriptions but only 18% of drug spending, saving over $373 billion annually. Biosimilar adoption remains below 20% despite some products reaching over 60% market share within three years.
Mar 21, 2026
Creative Biolabs has expanded its preclinical research capabilities with an upgraded rodent behavioral profiling platform for CNS drug discovery and enhanced circRNA and nucleic acid analysis platforms for gene therapy development.
Mar 20, 2026
The global AI in clinical trials market is expected to grow from $2.09 billion currently to $18.62 billion by 2040, driven by enhanced patient recruitment, optimized trial designs, and automation that reduces time and costs in drug development.
Mar 17, 2026
Prognica Labs and NextGen Immuno Therapeutics announced a strategic partnership to advance AI-powered immune diagnostics and personalized medicine across the GCC, India, and the United States, targeting oncology, transplant medicine, and autoimmune disorders.
Mar 15, 2026
Novartis reported annual operating income of $17.07 billion for 2025, up 17.40% year-over-year, while AlphaValue/Baader raised its price target to 136 Swiss francs but maintained a "reduce" rating due to valuation concerns.
Mar 12, 2026
Multiple institutional investors modified their Moderna Inc positions during recent quarters, with some funds increasing stakes while others reduced or exited positions, according to 13F filings.
Mar 12, 2026
India's pharmaceutical industry, valued at Rs. 5.41 lakh crore in 2025, is transitioning from a generics powerhouse to an innovation-driven sector focused on biosimilars, complex formulations, and global R&D capabilities.
Mar 12, 2026
The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
Mar 11, 2026
The FDA is expected to issue draft guidance reducing testing requirements for biosimilar drugs, potentially lowering development costs by USD 20 million. The move comes as the biosimilars market shows strong growth, with major launches in 2025.
Mar 08, 2026
Healthcare sector surged 10% since Q4 2025, outpacing all S&P 500 sectors as investors rotate from tech to pharmaceutical value plays. Major drugmakers demonstrate resilience following Medicare price negotiations implementation.
Mar 04, 2026
Moderna has settled with Arbutus and Genevant, facing a potential $1.3 billion liability contingent on Federal Circuit's decision. Multiple institutional investors have increased their stakes in the biotech company during recent quarters.
Mar 03, 2026
New research shows 73% of AI users in clinical trials report the technology met or exceeded expectations, with 70% confirming improvements in data accuracy and 93% of organizations already using or investigating AI applications.
